Biotech antisense specialist focused on RNA therapies
Researchers have published long-term data showing that very high blood levels of the tau marker p‑tau217 predict a 38% risk of cognitive impairment within five years and 78% within ten. Trials are using the test to recruit volunteers while Scotland has started a primary‑care rollout of p‑tau testing to study real‑world use.